Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

30 Oct 2007 10:02

ViaLogy PLC30 October 2007 30 October 2007 ViaLogy plc AGM statement At the Annual General Meeting of ViaLogy PLC (VIY), the AIM-quoted technologycompany that is a leading innovator of network-centric, real time signalprocessing platforms for sensor applications, to be held at 10am today, theChairman, Terry Bond, will make the following statement. "It has been a year since shareholders approved the acquisition of the remainderof ViaLogy's share capital and the change of name to ViaLogy plc. During theyear the company has achieved a number of significant technical and productmilestones and the transition from research and development-driven activities tothe commercialisation of the technology is well underway. Over the next year ViaLogy will roll-out several products, principally SPM,MicroSPM and MPEX, initially targeting the defence, oil & gas and enterprisemarkets. These applications are based on ViaLogy's proprietary,patent-protected Quantum Resonance Interferometry (QRI) signal processingtechnology that enables the detection and interpretation of very weak signalsfrom large amounts of information and background noise. Ultimately SPM providesa solution to the problem of sensor integration. SPM, Sensor Policy Manager, is an enterprise-grade software product for sensorprocessing and interoperability. Unlike other sensor management solutions thatwork only with sensors from a single vendor, ViaLogy SPM software automaticallydiscovers network-attached sensors from any vendor, fuses and normalises theirinputs for central monitoring, and invokes real-time actions based oncustomer-defined policies. The network-centric approach provides measurablebenefits for security, safety and surveillance. The technology can integrate upto thousands of sensors connected to wireless and wired networks without delaysor loss of coverage. One of the early adopters of the SPM technology was Cisco Systems, which hasimplemented the technology at its San Jose campus to support safety and securityoperations, enabling the automation of complex facility operations. ViaLogy hasalso negotiated contracts for further SPM installations in the US and Taiwan. MicroSPM, is a compact, hardware-based solutions for real-time video and sensordata processing. It is designed to automate and improve the speed andeffectiveness of security and surveillance activities, such as face recognitionin crowds; human, object and vehicle detection and counting; and license platereading, in particular under difficult environment conditions. Reducingreliance on multiple human operators for analysis and decision-making. MPEX (Multi Parallax Exploitation) Electronic Eye, is a major advancement incomputer vision and video surveillance technology. In development with BoeingPhantom Works, the electronic eye is capable of 360 degree video processing,based on bionic principles that mimic the optical movements of some insects andreptiles. Initial applications for this technology will be for the detection ofvery fast moving targets such as missile interceptors, deployment of fast movingground vehicles and airborne platforms like unmanned aerial vehicles. Beyond these products other opportunities exist for ViaLogy's technology asannounced during the year. A technical breakthrough to improve the stability andperformance of miniature vibratory gyroscopes, achieved in collaboration withNASA's Jet Propulsion Laboratory and Boeing, which has wider applications in theemerging Micro Electro-Mechanical Systems (MEMS) market; the development of thedual-beam Reverse Photo-Acoustic Spectrometer (REPAS) with the Oak RidgeNational Laboratory for the detection of chemical, biological, radiological,nuclear and explosive materials; and, selection by the US Department of Defenseto provide a command and control platform for joint experiments to support thenext generation Joint Force Protection Advanced Security (JFPASS). An investment is being made to establish a strong sales and marketing team inorder for the Company to be able to exploit the opportunities available to it bybuilding relationships with potential partners and identifying global saleschannels. As you can see it is an exciting time for ViaLogy and the Board is enthusiasticand confident about the progress the Company will make over the next year andbeyond." End For further information please contact: ViaLogyTerry Bond, Chairman +44 (0)1235 834734 or 07860 842756Seymour Pierce Mark Percy, Nominated Adviser +44 (0)20 7107 8000Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defence andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.